Juno Therapeutics Inc (JUNO) - Financial and Strategic SWOT Analysis Review

September 2017 | 50 pages | ID: J7EC67C016CEN
GlobalData

Abstracts

Juno Therapeutics Inc (JUNO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Key manufacturing facilities – A list of key manufacturing facilities of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Juno Therapeutics Inc (Juno) is a clinical-stage company that develops novel cellular immunotherapies. The company formulates cell-based cancer immunotherapies based on platforms such as chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to identify and kill cancer cells. It develops CD19 CAR and WT-1 TCR clinical programs which include numerous product candidates in clinical development for several hematologic malignancies in adults and children. Juno offers CAR and TCR product candidates targeting multiple cancer types. The company works in collaboration with various cancer centers. Juno is headquartered in Seattle, Washington, the US.

Juno Therapeutics Inc Key Recent Developments

Sep 21,2017: Juno Therapeutics Opens New Headquarters and Research Center
Aug 09,2017: Editas Medicine Achieves Milestone Under Juno Therapeutics Collaboration for Technical Progress Towards Overcoming the Tumor Microenvironment
Aug 03,2017: Juno Therapeutics Reports Second Quarter 2017 Financial Results
May 23,2017: Juno Therapeutics Appoints Jay Flatley to Board of Directors
May 04,2017: Juno Therapeutics Reports First Quarter 2017 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Juno Therapeutics Inc - Key Facts
Juno Therapeutics Inc - Key Employees
Juno Therapeutics Inc - Major Products and Services
Juno Therapeutics Inc - History
Juno Therapeutics Inc - Company Statement
Juno Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Juno Therapeutics Inc - Business Description
Juno Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Juno Therapeutics Inc - Strengths
Juno Therapeutics Inc - Weaknesses
Juno Therapeutics Inc - Opportunities
Juno Therapeutics Inc - Threats
Juno Therapeutics Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Juno Therapeutics Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 09, 2017: Editas Medicine Achieves Milestone Under Juno Therapeutics Collaboration for Technical Progress Towards Overcoming the Tumor Microenvironment
Aug 03, 2017: Juno Therapeutics Reports Second Quarter 2017 Financial Results
May 23, 2017: Juno Therapeutics Appoints Jay Flatley to Board of Directors
May 04, 2017: Juno Therapeutics Reports First Quarter 2017 Financial Results
Apr 19, 2017: Juno Therapeutics Appoints Rupert Vessey to Board of Directors
Apr 17, 2017: Juno Therapeutics Appoints Sunil Agarwal as President of Research and Development
Mar 01, 2017: Juno Therapeutics Reports Fourth Quarter and 2016 Financial Results
Jan 27, 2017: Juno Therapeutics Appoints Corsee D. Sanders as Executive Vice President and Head of Development Operations
Nov 09, 2016: Juno Therapeutics Reports Third Quarter 2016 Financial Results
Nov 03, 2016: Juno Therapeutics to Highlight CAR T Advances in B-cell Malignancies at ASH 2016

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Juno Therapeutics Inc, Key Facts
Juno Therapeutics Inc, Key Employees
Juno Therapeutics Inc, Major Products and Services
Juno Therapeutics Inc, History
Juno Therapeutics Inc, Subsidiaries
Juno Therapeutics Inc, Joint Venture
Juno Therapeutics Inc, Key Competitors
Juno Therapeutics Inc, Ratios based on current share price
Juno Therapeutics Inc, Annual Ratios
Juno Therapeutics Inc, Annual Ratios (Cont.1)
Juno Therapeutics Inc, Interim Ratios
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Juno Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Juno Therapeutics Inc, Performance Chart (2013 - 2016)
Juno Therapeutics Inc, Ratio Charts
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

Tragara Pharmaceuticals Inc
Novartis Pharmaceuticals Corp
NeoGenomics Inc
ImmuneXcite Inc
Eiger BioPharmaceuticals Inc